Back to discover
Disease

Hepatomegaly

Late-stage therapeutic developmentEmerging research
MeSHHepatomegaly
1
Publications
7
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders

Clinical trial2026-09-01Status changed to Active, not recruiting · ClinicalTrials.gov

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Research2023-06-24Annals of hepatology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2029.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Results expected Q1 20292026-09-01
Clinical Milestones1View
Results expected 1
Activity timeline1

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Imigluceraseapproved

Original application approval — Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in pa… (1997)

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
7
All trials
2
Active
2
Late-stage
3
Completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
1997emaOriginal application approval — Imiglucerase· Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 paper

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Annals of hepatology · 2024 · 472 cites
Recent publications

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Annals of hepatology · 2024 · 472 cites
Major themes1
  • Non-alcoholic Fatty Liver Disease1
Leading journals1
  • Annals of hepatology1
Leading researchers8
  • Abdelmalek MF1
  • Anstee QM1
  • Arab JP1
  • Arrese M1
  • Bataller R1
  • Beuers U1
  • Boursier J1
  • Bugianesi E1
Affiliations (unnormalised)6
  • Angers University Hospital1
  • Antwerp University Hospital1
  • Austral University Hospital1
  • Barcelona Institute for Global Health (ISGlobal)1
  • Baylor College of Medicine1
  • Centre for Liver Disease Research1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Enlargement of the liver.

Identifiers
MeSHHepatomegaly
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.